Giới thiệu
- Rifamycin SV, FDA-approved in 2018, is indicated for traveler's diarrhea caused by non-invasive strains of E. coli in adults.
- Rifamycin SV is a poorly absorbed member of the rifamycin (technically ansamycin) class of antibiotics that was actually the first to be used in clinical practice (1963). In theory the product's MMX (multimatrix) technology allows for release of active antibiotic only after it reaches pH levels of ≥7 in the distal small bowel and colon, with an additional 1 hour delay upon reaching this pH.
- Mechanism of action: inhibition of the beta-subunit of bacterial DNA-dependent RNA polymerase, blocking one of the steps in DNA transcription.
Liều cho trẻ em
| Dose (Age >28 Days) | Safety and efficacy not established |
|---|---|
| Max/Day | - |
Chỉnh liều trên bệnh nhân suy thận
| Half-life bình thường | No data |
|---|---|
| Half-life ESRD | No data |
| Liều bình thường | 388 mg po q12h |
| Chỉnh liều suy thận | No dosage adjustment |
| Hemodialysis | No data |
| CAPD | No data |
| CRRT | No data |
| SLED | No data |
Chỉnh liều trên bệnh nhân suy gan
| Mild impairment (Child-Pugh Class A) | Không chỉnh liều |
|---|---|
| Moderate impairment (Child-Pugh Class B) | Không chỉnh liều |
| Severe impairment (Child-Pugh Class C) | Không chỉnh liều |